NUTLEY, N.J., Oct. 16 /PRNewswire/ -- New study results will be unveiled from Roche’s robust Phase III clinical development program for its investigational anti-anemia drug, C.E.R.A. (Continuous Erythropoietin Receptor Activator) at the upcoming 39th Annual Meeting of the American Society of Nephrology in San Diego on November 14-19.
Among the highlights will be the first public presentation, in the United States, of data from the C.E.R.A. Phase III clinical development program -- the largest of its kind -- with results from the correction and maintenance studies in chronic kidney disease (CKD) patients on dialysis and not on dialysis.
Additional Roche supported observational studies discuss the impact of CKD and anemia on the patient and cost of care.
Presentation Date & Time Author Abstract Title Type of Presentation C.E.R.A. Presentations Author: C.E.R.A. (Continuous Poster November 18 I.C. Macdougall, Erythropoietin Receptor 10:00 AM - 12:00 PM R. Walker, Activator) Administered R. Provenzano, at Extended Intervals F. de Alvaro, Corrects Anemia and H.R. Locay, P.C. Maintains Stable Hb Levels Nader, F. in Patients with CKD not Locatelli, F.C. on Dialysis Dougherty Author: C.E.R.A. (Continuous Poster November 18 M. Klinger, M. Erythropoietin Receptor 10:00 AM - 12:00 PM Arias, V. Activator) Administered Vargemezis, A. at Extended Intervals Besarab, W. Corrects Hb levels in Sulowicz, T. Patients with CKD on Gerntholtz, K. dialysis Ciechaanowski, F.C. Dougherty Author: Adequate Hb levels are Poster November 18 N.W. Levin, E. Maintained with IV C.E.R.A. 10:00 AM - 12:00 PM Imbasciati, C. (Continuous Erythropoietin Combe, M.V. Receptor Activator) Rocco, C.E. Lok, Administered up to Once S.M. Donnelly, Monthly in Patients with F.C. Dougherty CKD on Dialysis Irrespective of Age, Gender or Diabetic Status Author: IV C.E.R.A. (Continuous Poster November 18 S. Fishbane, N.W. Erythropoietin Receptor 10:00 AM - 12:00 PM Levin, J.F.E. Activator) Once Every 2 Weeks Mann, J.L. Lewis, or Once Monthly Maintains M. Bernado, N.M. Stable Hb Levels after Lunde, F.C. Converting Directly from IV Dougherty Epoetin 1-3 Times per Week in Patients with CKD on Dialysis Author: SC C.E.R.A. (Continuous Poster November 18 J-P. Ryckelynck, Erythropoietin Receptor 10:00 AM - 12:00 PM K. Harris, R. Activator) Administered up Selgas, T. to Once Monthly in Patients Stompor, E. with CKD on Dialysis Maintains Ladanyi, S. Adequate Hb Levels Regardless Opatrna, F.C. of Age, Gender or Diabetic Dougherty Status Author: SC C.E.R.A. (Continuous Poster November 18 F. Locatelli, Erythropoietin Receptor 10:00 AM - 12:00 PM W. Sulowicz, Activator) Once Every 2 K. Harris, R. Weeks or Once Monthly Selgas, J. Maintains Stable Hb Levels Kaufman, M. after Converting Directly Klinger, F. from SC Epoetin 1-3 Times Malberi, F.C. per Week in Patients with Dougherty CKD on Dialysis Author: C.E.R.A. Acts Differently Poster November 18 M. Jarsch, M. at the Erythropoietin (EPO) 10:00 AM - 12:00 PM Brandt, M. Receptor Compared with Kubbies, M. Epoetin Beta: UT-7 and CD34+ Lanzendorfer, A. cell stimulation assays Haselbeck, Additional Roche Presentations Author: A Retrospective Claims Poster November 16 Jay Wish, Kathy Analysis of Anemia 10:00 AM - 12:00 PM Schulman, Amy Treatment Patterns in Law, Michael del Patients With Chronic Aguila Kidney Disease With and Without Diabetes Author: Consistency of Pre- Poster November 16 T. Roberts, MS, ESRD Erythropoietin 10:00 AM - 12:00 PM A. Murry, MD, (EPO) Use and Hospital MSc, D. Days At and Following Gilbertson, PhD, Hemodialysis Initiation A.J. Collins, MD, FACP Author: Pre-ESRD Erythropoietin Poster November 16 T. Roberts, MS, (EPO) Treatment and 10:00 AM - 12:00 PM D. Gilbertson, Associated Hospitalization PhD, A.J. Collins and Mortality Outcomes MD After Dialysis Initiation Author: The Association of Poster November 17 Jiannong Liu, Persistently Low 10:00 AM - 12:00 PM PhD, Haifeng Guo, Hemoglobin Levels with MS, David T. Medical Expenditures in Gilbertson, PhD, Dialysis Patients Allan J. Collins, MD Author: Association Between Poster November 17 Robert N. Foley, Missed Dialysis Sessions 10:00 AM - 12:00 PM MB, Qi Li, MS, and Hemoglobin Variability David T. in the US Gilbertson, PhD, Allan J. Collins, MD, Stephan C. Dunning, MGIS Author: Medication Burden in Poster November 18 Jay Wish, Kathy Patients With Chronic 10:00 AM - 12:00 PM Schulman, Amy Kidney Disease and Law, Michael del Anemia Treated With Aguila and Without Erythropoiesis-Stimulating Agents Author: Cost Burden of Anemia Poster November 18 Jay Wish, Kathy in a Predialysis Cohort 10:00 AM - 12:00 PM Schulman, Amy of Patients With Chronic Law Kidney Disease Author: Dosing Patterns, Abstract ASN Abstract Book Saul Nurko, Dominant Intervals, Publication Only Rita Spirko, and Hemoglobin Control Amy Law, Iris in Predialysis Patients Kingma-Johnson, With Chronic Kidney Vincent Dennis Disease Treated With Erythropoiesis-Stimulating Agents
Interested journalists may view the titles of ASN abstracts selected for presentation, as well as the meetings schedule online at http://www.abstracts2view.com/asn.
Roche
CONTACT: Shelley Rosenstock, Roche, +1-973-562-2373,shelley.rosenstock@roche.com; Diana Scott, MS&L, +1-212-468-4271,diana.scott@mslpr.com, for Roche
Web site: http://www.abstracts2view.com/asn/
